378 related articles for article (PubMed ID: 8888951)
21. Proliferating cell nuclear antigen (PCNA) expression of megakaryocytopoiesis in normal human bone marrow and reactive lesions with special emphasis on HIV-myelopathy.
Thiele J; Titius BR; Kvasnicka HM; Bertsch HP; Erdmann S; Fischer R
Pathol Res Pract; 1994 Jan; 190(1):42-50. PubMed ID: 7520574
[TBL] [Abstract][Full Text] [Related]
22. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
23. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
[TBL] [Abstract][Full Text] [Related]
24. Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up.
Thiele J; Kvasnicka HM; Zerhusen G; Vardiman J; Diehl V; Luebbert M; Schmitt-Graeff A
Ann Hematol; 2004 Aug; 83(8):513-21. PubMed ID: 15173958
[TBL] [Abstract][Full Text] [Related]
25. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
26. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome.
Wu L; Li X; Chang C; Ying S; He Q; Pu Q
Int J Lab Hematol; 2008 Oct; 30(5):390-9. PubMed ID: 19046314
[TBL] [Abstract][Full Text] [Related]
27. Megakaryocytopoiesis in bone marrow biopsies of patients with acquired immunodeficiency syndrome (AIDS). An immunohistochemical and morphometric evaluation with special emphasis on myelodysplastic features and precursor cells.
Thiele J; Titius BR; Quitmann H; Fischer R; Salzberger B; Dienemann D; Stein H
Pathol Res Pract; 1992 Aug; 188(6):722-8. PubMed ID: 1437834
[TBL] [Abstract][Full Text] [Related]
28. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS).
Cantù Rajnoldi A; Fenu S; Kerndrup G; van Wering ER; Niemeyer CM; Baumann I;
Ann Hematol; 2005 Jul; 84(7):429-33. PubMed ID: 15838669
[TBL] [Abstract][Full Text] [Related]
30. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
31. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
32. The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows.
Mundle S; Venugopal P; Shetty V; Ali A; Chopra H; Handa H; Rose S; Mativi BY; Gregory SA; Preisler HD; Raza A
Int J Hematol; 1999 Apr; 69(3):152-9. PubMed ID: 10222652
[TBL] [Abstract][Full Text] [Related]
33. Increased angiogenesis in the bone marrow of HIV-positive patients with myelodysplasia.
Patsouris E; Korkolopoulou P; Androulaki A; Douzinas E; Kosmopoulou O; Kordossis T
Pathology; 2003 Aug; 35(4):330-5. PubMed ID: 12959769
[TBL] [Abstract][Full Text] [Related]
34. [LAT (linker for activation of T cells): a useful marker for megakaryocyte evaluation on bone marrow biopsies].
Ungari M; Pellegrini W; Borlenghi E; Marocolo D; Ubiali A; Agazzi C; Pich A; Franco V; Facchetti F
Pathologica; 2002 Dec; 94(6):325-30. PubMed ID: 12540999
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS.
Amigo ML; del Cañizo MC; Rios A; Garcia MA; Caballero MD; Martin A; Bermejo N; Vilches P; San Miguel JF
Bone Marrow Transplant; 1999 May; 23(10):997-1002. PubMed ID: 10373064
[TBL] [Abstract][Full Text] [Related]
36. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
37. [A study of hypoplastic myelodysplastic syndrome].
Sato Y; Mituhashi S; Otani K; Kamoshita M; Hasegawa Y; Ninomiya H; Nagasawa T; Abe T
Rinsho Ketsueki; 1993 Nov; 34(11):1431-7. PubMed ID: 8254904
[TBL] [Abstract][Full Text] [Related]
38. p53 overexpression in myeloid leukemic disorders is associated with increased apoptosis of hematopoietic marrow cells and ineffective hematopoiesis.
Orazi A; Kahsai M; John K; Neiman RS
Mod Pathol; 1996 Jan; 9(1):48-52. PubMed ID: 8821956
[TBL] [Abstract][Full Text] [Related]
39. [Chromosomal structural changes in patients with myelodysplastic syndrome].
Yu Y; Liu XP; Liu SH; Yu MH; Zhang Y; Xiao ZJ
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2693-7. PubMed ID: 18167247
[TBL] [Abstract][Full Text] [Related]
40. What does apoptosis have to do with clinical features in myelodysplastic syndrome?
Ramos F; Fuertes-Núñez M; Suárez-Vilela D; Fernández-López A
Haematologica; 2002 Apr; 87(4):381-91. PubMed ID: 11940482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
